Table 1.
Summary of the literature on MWA for ICCA.
| Reference of Original Publication | Year of Publication | Technique(s) Analyzed | Number of Patients Included |
Number of Treated Lesions |
Size (Range; cm) |
OS 1, 3, 5 Years (%) |
RFS 1, 3, 5 Years (%) |
|---|---|---|---|---|---|---|---|
| [26] | 2011 | MWA | 15 | 24 | 3.2 (1.3–9.9) | 60, -, - | - |
| [23] | 2012 | MWA | 18 (6) | 25 | 2.5 (0.7–4.3) | 36.3, 30.3, 30.3 | - |
| [27] | 2015 | MWA/TACE | 26 | 39 | 3.6 (2.5–6.5) | 69.2, 61.5, - | - |
| [28] | 2018 | MWA | 107 | 171 | 93.5, 39.6, 7.9 | 41.5, -, - | |
| [29] | 2018 | RFA vs. MWA | 20 | 50 | 1.8 (0.5–4.7) | - | - |
| [30] | 2019 | RFA vs. MWA | 71 (35) | 98 (50) | 3.6 ** (2.2–7.2) | 95, 75, 68 ** | 79, 59, 55 ** |
| [31] | 2019 | MWA | 78 | 106 | 3.1 (0.8–5) | 78.9, 52.2, 35 | 78.9, 19.9, - |
| [32] | 2019 | MWA vs. surgery | 121 (56) | 136 (62) | 2.7 (0.8–5) | 81.2, 42.5, 23.7 ** | 70.3, 33.1, - ** |
| [33] | 2020 | MWA/TACE | 275 (92) | - | 5.7 | 50, 21.5, 6.1 | 41.1, 21.5, 6.1 |
| [34] | 2020 | MWA | 221 {32} | 285 | - | - | - |
| [35] | 2020 | MWA/RFA | 27 (3) * | 33 | 2.1 (2.0–2.8) | 88.9, 40.7, 14.8 | - |
| [36] | 2021 | MWA | 52 | 74 | 3.1 (0.8–5) | 87.4, 51.4, 35.2 | 68.9, 56.9, 56.9 |
MWA = microwave ablation; RFA = radio radiofrequency ablation; TACE = transarterial chemoembolization; OS = overall survival, RFS: recurrence free survival. * Results for different ablation, not separated; ** Results for MWA; () = CCA; { } = ICCA.